TYK2 and COVID-19: Briefly, TYK2 encodes for tyrosine kinase 2 (TYK2) a protein partially targeted by Janus kinase (JAK) inhibitors like baricitinib, that have been approved for rheumatoid arthritis and successfully repurposed for severe COVID-19, although predating possible evidence from genetic studies30–32.